Format

Send to

Choose Destination
Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587.

Therapeutic options for Acinetobacter baumannii infections.

Author information

1
Hospital Clinic, Department of Clinical Microbiology, Villarroel, 170; 08036 Barcelona, Spain. jvila@ub.edu

Abstract

Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be considered the paradigm of nosocomial multiresistant bacteria. This review analyzes the evolution of antimicrobial resistance and the molecular bases associated with the increase in antimicrobial resistance, as well as the current treatment of Acinetobacter infections. Although controversy remains, the pooled data suggest that infections by A. baumannii may be associated with considerable attributable mortality. Moreover, in cases of pneumonia and bacteraemia, inappropriate treatment is associated with, among other factors, mortality. Therefore, treatment should be carefully considered.

PMID:
18312160
DOI:
10.1517/14656566.9.4.587
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center